Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort

HIV Infection Clinical Trial

— ZINC  

Official title:

Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01934803
• Other study ID #: H-31901
• Secondary ID: U01AA021989
• Status: Completed
• Phase: N/A
• Start date: October 2013
• Est. completion date: November 8, 2018

Study information

• Verified date: November 2018
• Source: Boston Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a double-blinded randomized controlled trial (RCT) to assess the efficacy of zinc supplementation vs. placebo among 250 HIV-infected Russians from the Russia ARCH Cohort, who are ART-naive at enrollment and have a recent history of heavy drinking.

Description:

The combination of heavy alcohol consumption and HIV infection is associated with increased mortality, HIV disease progression, acute myocardial infarction (AMI) and a proinflammatory state characterized by increased biomarker levels of inflammation. Heavy alcohol use and HIV infection are both causes of microbial translocation, the process by which bacterial products from the gastrointestinal (GI) tract leak across the GI membrane to the portal circulation. Microbial translocation causes immune activation leading to end organ damage. Alcohol can cause microbial translocation via zinc deficiency. Zinc deficiency is common among HIV-infected heavy drinkers and linked to high mortality rates. Zinc supplementation is affordable, available, does not interfere with ART, and has minimal adverse drug reactions. In animal models zinc reduces ethanol associated microbial translocation. In human studies zinc slows HIV disease progression and reduces levels of inflammatory biomarkers which are strongly linked to mortality. Given zinc's potential efficacy we propose to conduct Zinc for INflammation and Chronic disease in HIV (ZINC HIV), a double-blinded randomized controlled trial to assess the efficacy of zinc supplementation vs. placebo among 250 HIV+ Russians, who are ART-naive at enrollment and have a recent history of heavy drinking. We will recruit most of our participants from the Russia cohort within the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium study. Our specific aims will test the efficacy of zinc supplementation, compared to placebo to (1) improve markers of mortality as measured by the VACS index; (2) slow HIV disease progression as measured by CD4 cell count; (3) improve markers of AMI risk as measured by the Reynolds risk score; and (4) lower levels of microbial translocation and inflammation as measured by serum biomarkers. We hypothesize that as compared with placebo, patients receiving zinc supplementation will have significantly lower AMI and mortality risk as measured by the VACS index and Reynolds risk scores; higher CD4 cell counts; lower levels of biomarkers for microbial translocation and inflammation. Importantly, if our hypotheses are true, zinc supplementation could ultimately become a standard adjunctive therapy complementing alcohol interventions among HIV-infected persons even in resource limited environments. PUBLIC HEALTH RELEVANCE: The combination of heavy alcohol consumption and HIV infection results in serious health problems and an increased risk of death. Although it is not exactly clear how alcohol and HIV do this, inflammation appears to play an important role. Zinc supplementation has anti-inflammatory properties. This study is designed to see if giving zinc supplementation to HIV infected people who are heavy drinkers reduces the risk of serious health problems and death.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 254
• Est. completion date: November 8, 2018
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18-70 years old

• HIV-infected

• ART naïve

• Heavy alcohol consumption [i.e., NIAAA at-risk drinking levels] in the past 30 days

• Provision of contact information for two contacts to assist with follow-up;

• Stable address within St. Petersburg or districts within 100 kilometers of St. Petersburg;

• Possession of a home or cellular telephone

Exclusion Criteria:

• Not fluent in Russian

• Cognitive impairment resulting in inability to provide informed consent based on assessor assessment

• Pregnancy

• Breastfeeding

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Alcohol Drinking
• Alcohol Use
• HIV Infection
• HIV Infections

Intervention

Dietary Supplement:
• Zinc gluconate
Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
• Placebo

Locations

Country	Name	City	State
Russian Federation	Pavlov State Medical University	St. Peterburg

Sponsors (2)

Lead Sponsor	Collaborator
Boston Medical Center	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improved markers of mortality as measured by change in VACS index		Participants will be followed for up to 18 months
Secondary	Slower HIV disease progression as measured by change in CD4 cell count		Participants will be followed for up to 18 months
Secondary	Improved markers of AMI risk as measured by the Reynolds risk score		Participants will be followed for up to 18 months
Secondary	Lower biomarker levels of microbial translocation and inflammation as measured by sCD-14, IL-6, D-dimer, IFABP, LBP		Participants will be followed for up to 18 months

External Links

•   Website for the Uganda, Russia, Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS